Novo Nordisk (NYSE: NVO), a Denmark-based pharmaceutical company, has this week published results from a Phase III study assessing the impact of the GLP-1 receptor agonist Ozempic (semaglutide) on the progression of renal impairment in individuals with type 2 diabetes (T2D) and chronic kidney disease (CKD). Following the trial’s discontinuation last year after an efficacy readout, Novo Nordisk announced that the study successfully met its combined primary endpoint. The treatment reduced by 24% the risk of kidney disease progression and the combined risk of cardiovascular and kidney death compared to placebo.
The trial also achieved its confirmatory secondary endpoints, with the medicine showing a safety and tolerability profile in line with previous studies.
Novo Nordisk is now preparing to submit these data to regulatory authorities to back an indication extension for Ozempic.- Flcube.com
